Heterogeneous expression of immunotherapy response markers in non-small cell lung cancer with hyperactive NRF2 pathway: PD-L1 and beyond.

doi:10.1016/j.redox.2025.103889

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Heterogeneous expression of immunotherapy response markers in non-small cell lung cancer with hyperactive NRF2 pathway: PD-L1 and beyond.

Redox biology - 1 Nov 2025

Almeida-Lima Karoline, Falchetti Marcelo, Dos Santos Barbara, Delgobo Marina, Gonçalves Rosângela Mayer, Somensi Nauana, Zancanaro Helena Souza, de Freitas Juan Nóbrega, das Neves Raquel Nascimento, Golfetto Lisléia, Leidens Danusa, Silveira Daniela Augustin, Bassani Nicklas, Bishop Alexander James Roy, Vieira Daniella Serafin Couto, Forcelini Cassiano Mateus, Zanotto-Filho Alfeu

Abstract excerpt

Activating mutations in the NRF2 pathway characterize an aggressive, molecularly distinct subtype of non-small cell lung cancer (NSCLC) associated with poor prognosis and resistance to immune checkpoint inhibitors (ICI). In this study, we used a validated NRF2 transcriptional signature along with a literature-curated, immune-related 47-gene set associated with favorable responses to ICI (the "ICI-Immune"...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Carcinoma, Non-Small-Cell Lung

Share to Gene Expression Regulation, Neoplastic

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to NF-E2-Related Factor 2

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 41106040
DOI: 10.1016/j.redox.2025.103889
PMCID: PMC12557609

Genes

KEAP1
C2
CD274
NFE2L2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heterogeneous expression of immunotherapy response markers in non-small cell lung cancer with hyperactive NRF2 pathway: PD-L1 and beyond.PMID 41106040Read ↗

Pan-cancer scale screening reveals NRF2 associated immunoevasive characteristics in non-small cell lung cancer and squamous malignanciesSemantic proximity Read ↗

Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma.Semantic proximity Read ↗

KEAP1-Mutant Lung Cancers Weaken Anti-Tumor Immunity and Promote an M2-like Macrophage Phenotype.Semantic proximity Read ↗

NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.Semantic proximity Read ↗

Integrative omics analysis identifies subtypes with therapeutic implications in lung adenocarcinoma harboring KEAP1/NFE2L2Semantic proximity Read ↗

Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancerSemantic proximity Read ↗

KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?Semantic proximity Read ↗

NRF2 pathway activation and SPP1⁺TREM2⁺ macrophages drive chemoradiotherapy resistance in esophageal squamous cell carcinomaSemantic proximity Read ↗

KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC.Semantic proximity Read ↗

NRF2 Participates in the Suppressive Tumor Immune Microenvironment of KRAS/KEAP1 Co-Mutant Non-Small Cell Lung Cancer by Inhibiting the STING PathwaySemantic proximity Read ↗

Deciphering immune heterogeneity in lung adenocarcinoma via machine learning-based Differential Phenotype Immune Score: TPX2 as a key biomarker for immunotherapy resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.